Report of Foreign Issuer (6-k)
December 27 2018 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: December 2018 (Report
No. 2)
Commission file number: 001-36578
BIOBLAST PHARMA LTD.
(Translation of registrant's name into English)
PO Box 318, Tel-Aviv, Israel 6100201
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):
¨
Results of the Meeting of Shareholders
of the Company
At the Annual and Extraordinary
General Meeting of Shareholders of the Registrant held on December 27, 2018 (the “
Meeting
”), the Registrant’s
shareholders approved the agenda items as originally proposed. The agenda items that were approved are described further in Exhibits
99.1 and 99.2 to the Registrant’s Report on Form 6-K submitted to the Securities and Exchange Commission on December 6, 2018.
This Report of Foreign
Private Issuer on Form 6-K of the Registrant is incorporated by reference into the registration statement on Form F-3 (File
No. 333-206032) and the registration statements on Form S-8 (File No. 333-203114 and 333-210459) of the Registrant, filed with
the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not
superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Bioblast Pharma Ltd.
|
|
|
(Registrant)
|
|
|
|
|
|
By
|
/s/ Dr. Dalia Megiddo
|
|
|
Name: Dr. Dalia Megiddo
|
|
|
Interim Chief Executive Officer
|
|
|
|
|
|
Date: December 27, 2018
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioblast Pharma Ltd. (NASDAQ:ORPN)
Historical Stock Chart
From Jul 2023 to Jul 2024